305 related articles for article (PubMed ID: 20616662)
1. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.
Kamanamool N; McEvoy M; Attia J; Ingsathit A; Ngamjanyaporn P; Thakkinstian A
Medicine (Baltimore); 2010 Jul; 89(4):227-235. PubMed ID: 20616662
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
3. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
Lee YH; Woo JH; Choi SJ; Ji JD; Song GG
Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive treatment for proliferative lupus nephritis.
Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.
Liu LL; Jiang Y; Wang LN; Yao L; Li ZL
Drugs; 2012 Jul; 72(11):1521-33. PubMed ID: 22818016
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.
Jiang YP; Zhao XX; Chen RR; Xu ZH; Wen CP; Yu J
Medicine (Baltimore); 2020 Sep; 99(38):e22328. PubMed ID: 32957400
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis.
Touma Z; Gladman DD; Urowitz MB; Beyene J; Uleryk EM; Shah PS
J Rheumatol; 2011 Jan; 38(1):69-78. PubMed ID: 20952473
[TBL] [Abstract][Full Text] [Related]
8. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
[TBL] [Abstract][Full Text] [Related]
11. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
[TBL] [Abstract][Full Text] [Related]
12. Treatment for lupus nephritis.
Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
[TBL] [Abstract][Full Text] [Related]
13. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
14. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis: A PRISMA-compliant meta-analysis.
Zhang H; Zhou M; Han X; Yang Y; Yu X
Medicine (Baltimore); 2020 Aug; 99(33):e21121. PubMed ID: 32871981
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
Kuzuya K; Morita T; Kumanogoh A
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
[TBL] [Abstract][Full Text] [Related]
18. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
[TBL] [Abstract][Full Text] [Related]
19. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus versus mycophenolate mofetil as induction treatment and low-dose tacrolimus as treatment for lupus nephritis: a meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Nov; 82(9):754-762. PubMed ID: 36607421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
